Menu Search
Equities

Novo Nordisk A/S

NOVO B:CPH

Novo Nordisk A/S

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (DKK)439.40
  • Today's Change2.10 / 0.48%
  • Shares traded1.56m
  • 1 Year change22.31%
  • Beta0.9591
Data delayed at least 15 minutes, as of Sep 25 2020 15:59 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Novo Nordisk A/S had little change in net income (from 38.63bn to 38.95bn) despite revenues that grew 9.11% from 111.83bn to 122.02bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 15.75% to 16.03%.
Gross margin83.67%
Net profit margin32.73%
Operating margin43.40%
Return on assets32.62%
Return on equity73.24%
Return on investment63.67%
More ▼

Cash flow in DKKView more

In 2019, Novo Nordisk A/S did not generate a significant amount of cash. However, the company earned 46.78bn from its operations for a Cash Flow Margin of 38.34%. In addition the company used 11.51bn on investing activities and also paid 35.48bn in financing cash flows.
Cash flow per share20.01
Price/Cash flow per share16.80
Book value per share26.09
Tangible book value per share23.58
More ▼

Balance sheet in DKKView more

Novo Nordisk A/S has a Debt to Total Capital ratio of 6.45%, a higher figure than the previous year's 5.61%.
Current ratio1.09
Quick ratio0.8289
Total debt/total equity0.069
Total debt/total capital0.0645
More ▼

Growth rates in DKK

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 2.45% and 2.78%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)2.37%
Div growth rate (5 year)10.80%
Payout ratio (TTM)37.28%
EPS growth(5 years)10.22
EPS (TTM) vs
TTM 1 year ago		12.25
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.